Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 16

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 the EP 782 and EP 928 patents, respectively. A hearing on the main request for EP 782 is scheduled for September 2025. No hearing has yet been set for the main request with regard to EP 928. On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP 782 patent. In March 2025 the European Patent Office held an oral proceeding and upheld the validity of the claims of the EP 782 patent in an amended form.  On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP 928 patent. A hearing in the revocation action took place on September 18, 2024. Following the hearing, the UPC revoked EP 928. The Company strongly disagrees with this decision. On December 17, 2024, the Company appealed the decision to the UPC Court of Appeals.Vizgen  Vizgen, Inc. (“Vizgen”) and the Company were previously engaged in litigation in multiple jurisdictions relating to the Company’s Xenium products and Vizgen’s MERSCOPE products. On February 5, 2025, the Company and Vizgen resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.

15

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

ParseOn August 24, 2022, the Company filed suit against Parse Biosciences, Inc. (“Parse”) in the U.S. District Court for the District of Delaware alleging that Parse’s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the “981 patent”), 10,697,013 (the “013 patent”), 10,240,197 (the “197 patent”), 10,150,995 (the “995 patent”), 10,619,207 (the “207 patent”) and 10,738,357 (the “357 patent”). The Company seeks, among other relief, injunction relief and unspecified damages (including attorneys’ fees) in relation to Parse’s making, using, selling, offering to sell, exporting and/or importing in the United States Parse’s Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted